Lemonade

You may have heard of biomarker testing, but what does it actually mean, and how does it impact your treatment options? 🧬

To learn more about biomarker testing and how it can impact treatment, visit the link in our comments 🔗

When ovarian cancer comes back after treatment, this is called a recurrence. Sadly, this is something many people with ovarian cancer experience.

If the cancer returns more than 6 months after chemotherapy, it may be described as “platinum-sensitive”. This is a clinical term that can help guide treatment options, but we know hearing it can still feel overwhelming.

If you’re navigating a recurrence, support is available to help you cope with the physical and emotional impact 💙

To find more about platinum sensitive ovarian cancer, and where to get support, visit: https://pulse.ly/he8hua82nr

Use our Hereditary Cancer Risk Checker: https://pulse.ly/aefmx1bova

20% of ovarian cancer cases have a hereditary cause. This can be due to BRCA gene faults, Lynch syndrome or other rarer inherited gene changes.

Worried about inherited risk? Our Hereditary Risk Checker can help you understand your risk and give you clear information to take to your GP.

A drug originally developed for lung cancer may help improve ovarian cancer treatment.

New research from Mayo Clinic found that ovarian cancer cells can quickly adapt and resist PARP inhibitors — a common treatment.

But when researchers introduced brigatinib, a lung cancer drug, it helped block that resistance.

The result?

Cancer cells became more vulnerable to treatment — while healthy cells were largely unaffected.

It’s still early, but this kind of research is how breakthroughs happen. Not by starting from scratch, but by finding smarter ways to make existing treatments work better.

Read more here: https://bit.ly/4mmlk1t